Kyntra Bio swings to profit in Q2 on deconsolidation of subsidiary

Kyntra Bio

13/08/2026 21:11

Overview
US biopharma firm posted Q2 net income of $12.0 mln, reversing prior-year loss
Q2 revenue from continuing operations fell to negative $1.5 mln from $1.3 mln last year
Company ended Q2 with $95.7 mln in cash, equivalents, investments, and receivables

Outlook
Company expects interim analysis of FG-3246 Phase 2 trial in mCRPC in 4Q 2026
Kyntra Bio aims to initiate pivotal Phase 3 trial of roxadustat in LR-MDS in 4Q 2026
Company expects cash, equivalents, investments, and receivables to fund operations into 2028

Result Drivers
SUBSIDIARY DECONSOLIDATION - Net income driven by gain on deconsolidation of subsidiary

Company press release: ID:nGNX3Gz8j9

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
 
$11.97 mln
 
Q2 Net Income from Cont Ops
 
$11.97 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Kyntra Bio, Inc. is $35.00, about 393% above its August 12 closing price of $7.10

Reuters Recommended Reads
Aug 10 - Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Aug 13 - Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Aug 12 - Kura Oncology Q2 product revenue rises 57% on KOMZIFTI uptake

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)